Detalles de la búsqueda
1.
Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report.
Monaldi Arch Chest Dis
; 93(4)2022 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36426899
2.
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Oncologist
; 24(11): e1165-e1171, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30996007
3.
Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients.
Int J Mol Sci
; 20(9)2019 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31067796
4.
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Tumour Biol
; 40(11): 1010428318815047, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30486741
5.
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy.
Front Immunol
; 14: 1289434, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38304255
6.
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
Cancers (Basel)
; 14(23)2022 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36497292
7.
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Lung Cancer
; 140: 71-79, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31884129
8.
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
Oncol Rep
; 21(4): 1023-8, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19288004
9.
Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report.
J Cardiothorac Surg
; 14(1): 50, 2019 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30832704
10.
Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study.
Anticancer Res
; 39(3): 1403-1409, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30842175
11.
Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice.
Expert Rev Respir Med
; 13(3): 217-228, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30640563
12.
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
Lung Cancer Manag
; 9(1): LMT22, 2020 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32256708
13.
Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
Ann Transl Med
; 8(18): 1199, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33241048
14.
Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
Transl Cancer Res
; 8(Suppl 6): S618-S620, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35117144
15.
H-Prune through GSK-3ß interaction sustains canonical WNT/ß-catenin signaling enhancing cancer progression in NSCLC.
Oncotarget
; 5(14): 5736-49, 2014 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25026278
16.
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Cancer Cytopathol
; 121(10): 552-60, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23780873
17.
EGFR mutations detection on liquid-based cytology: is microscopy still necessary?
J Clin Pathol
; 65(6): 561-4, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22466414
18.
Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study.
Arch Surg
; 145(3): 233-8, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20231623
Resultados
1 -
18
de 18
1
Próxima >
>>